Blood lipids Sample Clauses

Blood lipids. Analyses of TC, HDL-C and TAG were carried out by Xx Xxx Xxxxxxxx at the Department of Clinical Biochemistry, King’s College Hospital. TC was determined using an enzymatic method using cholesterol esterase, cholesterol oxidase and peroxidase in a chemiluminescent reaction to produce a red quinoneimine dye. The increase in absorbance was measured as an endpoint reaction at 505/694 nm. For RISCK samples, inter-assay CVs were 1.1, 1.5 and 1.0 at 3.9, 5.2 and 5.7 mmol/L respectively. For MARINA samples inter-assay CVs were 1.1, 1.5 and 1.0 % at 3.9, 5.1 and 5.7 mmol/L respectively. HDL-C was analysed using a two-step automated procedure (Bayer Advia Direct HDL-C method). For RISCK samples CVs were 2.2, 2.1 and 2.5 at 0.91, 1.39 and 1.95 mmol/L respectively and for MARINA samples CVs were 2.2, 2.1 and 2.5 % at concentrations of 0.91, 1.39 and 1.95 mmol/L respectively. TAG was measured using an enzymatic assay (The Bayer Advia method). For RISCK samples, CVs were 2.5 and 1.5 at 1.32 and 2.36 mmol/L respectively and for MARINA samples CVs were 2.5 and 1.5 % at concentrations of 1.32 and 2.36 mmol/L respectively. LDL-C was calculated using the Friedwald formula if fasting plasma TG concentrations were < 4.49 mmol/L. The formula used was: LDL-C = TC - HDL-C - (TAG / 2.2) (Xxxxxxxxxx et al, 1972). For RISCK samples, plasma Apo B and Apo A1 were measured at the University of Surrey using commercially available kits (Randox, UK) that employ immuno- turbidimetric assays. The proportion of small dense LDL was measured by ultracentrifugation of the LDL fraction on an iodixanol gradient at the University of Surrey. Fasted plasma phospholipid fatty acids were measured by GC at the University of Reading as described by (Xxxxx et al, 2009). For MARINA samples, erythrocyte membrane phospholipid fatty acid composition measured using capillary gas liquid chromatography as described by Xxxxxxx et al. (2006). Mean inter-assay and intra-assay CVs were 3% and 2% respectively.
AutoNDA by SimpleDocs

Related to Blood lipids

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Substance Abuse Program The SFMTA General Manager or designee will manage all aspects of the FTA-mandated Substance Abuse Program. He/she shall have appointing and removal authority over all personnel working for the Substance Abuse Program personnel, and shall be responsible for the supervision of the SAP.

  • SUBSTANCE ABUSE The dangers and costs that alcohol and other chemical abuses can create in the electrical contracting industry in terms of safety and productivity are significant. The parties to this Agreement resolve to combat chemical abuse in any form and agree that, to be effective, programs to eliminate substance abuse and impairment should contain a strong rehabilitation component. The local parties recognize that the implementation of a drug and alcohol policy and program must be subject to all applicable federal, state, and local laws and regulations. Such policies and programs must also be administered in accordance with accepted scientific principles, and must incorporate procedural safeguards to ensure fairness in application and protection of legitimate interests of privacy and confidentiality. To provide a drug-free workforce for the Electrical Construction Industry, each IBEW local union and NECA chapter shall implement an area-wide Substance Abuse Testing Policy. The policy shall include minimum standards as required by the IBEW and NECA. Should any of the required minimum standards fail to comply with federal, state, and/or local laws and regulations, they shall be modified by the local union and chapter to meet the requirements of those laws and regulations.

  • Blood Donations An employee may be granted leave with pay, up to a maximum of two (2) hours, for donating blood during regularly scheduled hours of work.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • SHOP DRAWINGS, PRODUCT DATA AND SAMPLES 4.12.1 Shop Drawings are drawings, diagrams, schedules and other, data specially prepared for the Work by the Contractor or any Subcontractor, manufacturer, supplier or distributor to illustrate some portion of the Work.

  • NO DRUGS OR ALCOHOL For reasons of safety and public policy, in any Contract resulting from this procurement, the use of illegal drugs and/or alcoholic beverages by the Contractor or its personnel shall not be permitted while performing any phase of the work herein specified.

  • Substance Abuse Testing The Parties agree that it is in the best interest of all concerned to promote a safe working environment. The Union has no objection to pre-employment substance abuse testing when required by the Employer and further, the Union has no objection to voluntary substance abuse testing to qualify for employment on projects when required by a project owner. The cost and scheduling of such testing shall be paid for and arranged by the Employer. The Union agrees to reimburse the Employer for any failed pre-access Alcohol and Drug test costs.

  • Chemical Substances Supplier warrants that: (i) each chemical substance contained in Products is on the inventory of chemical substances compiled and published by the Environmental Protection Agency pursuant to the Toxic Substances Control Act and (ii) all Material Safety Data Sheets required to be provided by Supplier for Products shall be provided to DXC prior to shipment of the Products and shall be complete and accurate.

Time is Money Join Law Insider Premium to draft better contracts faster.